Spots Global Cancer Trial Database for Safety and Tolerability Study of SNS-314 for Advanced Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Safety and Tolerability Study of SNS-314 for Advanced Solid Tumors
Official Title: Phase 1 Open-Label Multicenter, Dose-Escalating, Clinical Study of the Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Profiles of SNS-314, a Novel Aurora Kinase Inhibitor, Administered to Patients With Advanced Solid Tumors
Study ID: NCT00519662
Conditions
Interventions
Study Description
Brief Summary: This is a study to assess the safety and tolerability of SNS-314 in advanced solid tumors in humans.
Detailed Description: Other objectives of this study include measuring pharmacokinetics (how long the drug can be measured in the blood).
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of Alabama, Birmingham, Birmingham, Alabama, United States
Stanford University Medical Center, Stanford, California, United States
University of New Mexico, Albuquerque, New Mexico, United States
Duke University, Durham, North Carolina, United States
Contact Details
Name: Glenn Michelson, MD
Affiliation: Sunesis Pharmaceuticals
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
